1. Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report 
Philip V. Hassard, Scott W. Binder, Viera Nelson, Eric A. Vasiliauskas 
Gastroenterology 
Volume 120, Issue 4, Pages (March 2001)
DOI: /gast
Copyright © 2001 American Gastroenterological Association Terms and Conditions

2. Fig. 1
BD involving the cecum and terminal ileum. Endoscopic view of (A) cecum and (B) terminal ileum before infliximab. Note improvement in deep ulcerations and inflammation 9 weeks later in the (C) cecum and (D) terminal ileum.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Histologic appearance of colon before and 9 weeks after infliximab. Note the marked reduction of inflammatory cells after the infusion. (A) Low magnification of the colonic mucosa showing distorted crypt architecture with a moderately increased mixed inflammatory cell infiltrate. (B) High magnification showing inflammatory infiltrate consisting of a mixture of neutrophils, lymphocytes, plasma cells, and eosinophils. Blood vessels exhibiting fibrinoid necrosis and perivascular infiltrates can be seen (arrow). (C) Posttreatment biopsy specimen of colonic mucosa shows restoration to normal crypt architecture and normal inflammatory cell infiltrate.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

4. Fig. 3
Inflammatory bowel disease activity indices used to measure response to infliximab infusions (arrows) in a case of BD. (A) CDAI. A CDAI score < 150 points (horizontal line) is considered clinical remission in a patient with CD. (B) IBDQ. IBDQ composite scores range from 32 to 224, with higher scores indicating better QOL. Patients in remission tend to score above 170 (horizontal line).
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions